Skip to content

Clinical efficacy and safety observation of Bushen Zhuangjin Decoction in the treatment of early and middlestage knee osteoarthritis

Study on the mechanism of Jiawei Bushen Zhuangjin Decoction in treating knee osteoarthritis based on transcriptomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000094
Enrollment
Unknown
Registered
2024-06-06
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis

Interventions

Experimental group:Bushen Zhuangjin Decoction

Sponsors

Henan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Patients who meet the diagnostic criteria for KOA (unilateral or bilateral); 2) Patients aged between 50 and 70 years old, both male and female; 3) The X-ray K-L grade of the knee joint belongs to grade II-III; 4) KOA stage belongs to the early and middle stages; 5) Patients with good basic conditions, suitable for drug treatment, and no obvious indications of surgery; 6) The patient had good compliance and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1) Have taken traditional Chinese medicine decoction, proprietary Chinese medicine or other Western medicine with KOA treatment in the past week; 2) Participants in other research projects before enrollment; 3) Patients with knee joint tumor, tuberculosis, rheumatism, rheumatoid arthritis, gouty arthritis and other diseases; 4) Patients who have undergone knee replacement; 5) Pregnant or planning to become pregnant or lactating women; 6) Patients with severe primary diseases of the heart, cerebrovascular and hematopoietic systems, mental diseases, malignant tumors, and liver and kidney dysfunction; 7) Participants in other clinical trials that affect the evaluation of the results of this study.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale/Score;The Western Ontario and McMaster;

Secondary

MeasureTime frame
Life quality score;Knee range of motion;TCM syndrome integral;

Countries

China

Contacts

Public ContactXiaofei Han

Henan University of Chinese Medicine

15837131696@139.com15837131696

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026